Corcept Therapeutics (NASDAQ:CORT) Issues Earnings Results

Corcept Therapeutics (NASDAQ:CORT) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.34, FiscalAI reports. The firm had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Second-quarter revenue rose 32% to $256.1 million, while net income increased to $43 million. Management raised full-year 2026 revenue guidance to $1.1 billion–$1.2 billion, citing strength in both endocrinology and oncology.
• LIFYORLI generated $47.6 million in its first quarter of availability, with more than 1,300 patients initiating treatment and over 1,000 prescribing physicians. Management highlighted broad payer coverage, NCCN preferred-regimen status, and a goal of exceeding $1 billion in U.S. annual revenue for platinum-resistant ovarian cancer.
• Korlym and the authorized generic continued to benefit from record new prescriptions, prescribers, and active patients, with specialty-pharmacy transition issues largely behind the company. Corcept expects its Cushing’s syndrome business to reach at least $2 billion in annual revenue by the end of the decade.
• The FDA accepted relacorilant’s resubmitted Cushing’s syndrome application and assigned a December 17, 2026 PDUFA date. Management believes approval could accelerate growth, supported by positive Phase III data and the potential for a more favorable safety profile than existing treatments.
• Corcept reported encouraging development plans across oncology, MASH, and ALS, including upcoming data from BELLA, STELLA, TRIDENT, and MONARCH. However, dazucorilant’s ALS program still requires a dose-titration study because gastrointestinal side effects caused most discontinuations in the Phase II trial.

Corcept Therapeutics Stock Down 1.3%

CORT traded down $1.24 during trading on Wednesday, hitting $92.95. 1,518,107 shares of the stock were exchanged, compared to its average volume of 1,582,921. The firm has a market capitalization of $9.98 billion, a P/E ratio of 265.58 and a beta of 0.47. The stock has a fifty day moving average price of $81.83 and a two-hundred day moving average price of $55.40. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $97.63.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Strong Q2 earnings beat: Revenue increased 31.7% year over year to $256.1 million, exceeding the $221.2 million consensus estimate. Diluted EPS was $0.36 versus expectations of $0.02, while operating profit rose 54.8% to $41.3 million. Corcept Therapeutics Q2 earnings
• Positive Sentiment: Raised 2026 revenue outlook: Corcept now expects full-year revenue of approximately $1.1 billion to $1.2 billion, above the roughly $1.0 billion analyst consensus. The higher outlook signals continued momentum in its oncology and Cushing’s syndrome businesses. Corcept raises 2026 revenue outlook
• Positive Sentiment: Improved financial performance: Net income rose 21.8% to $42.1 million, and the company ended the quarter with $111 million in cash and equivalents. Operating cash flow was $33.5 million, supporting financial flexibility. Corcept second-quarter financial results
• Neutral Sentiment: Mixed institutional and analyst signals: Recent institutional activity was divided, with 189 investors adding shares and 194 reducing positions. Analyst targets also vary widely—from $72 to $135—with a reported median of $91.50, indicating uncertainty about valuation after the stock’s substantial advance.
• Negative Sentiment: Analyst downgrade: Wolfe Research downgraded Corcept to Underperform, adding a bearish signal despite the strong results. Wolfe Research downgrade
• Negative Sentiment: Heavy insider selling: Company insiders made 34 open-market sales versus only two purchases during the past six months. Executives, including the CFO and CEO, were among those selling shares, which could raise valuation and confidence concerns for investors.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, CFO Atabak Mokari sold 40,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $81.15, for a total value of $3,246,000.00. Following the sale, the chief financial officer directly owned 16,130 shares in the company, valued at approximately $1,308,949.50. This trade represents a 71.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James N. Wilson sold 10,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total value of $832,000.00. Following the transaction, the director directly owned 1,094,543 shares in the company, valued at approximately $91,065,977.60. The trade was a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 300,000 shares of company stock worth $22,088,050 in the last three months. 20.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC raised its position in shares of Corcept Therapeutics by 9.3% during the fourth quarter. Corient Private Wealth LLC now owns 7,035 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 600 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Corcept Therapeutics during the fourth quarter valued at $456,000. Invesco Ltd. lifted its holdings in Corcept Therapeutics by 11.5% in the fourth quarter. Invesco Ltd. now owns 816,996 shares of the biotechnology company’s stock valued at $28,431,000 after buying an additional 84,413 shares during the period. FAS Wealth Partners Inc. boosted its holdings in Corcept Therapeutics by 0.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 310,018 shares of the biotechnology company’s stock worth $10,789,000 after buying an additional 1,700 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Corcept Therapeutics in the fourth quarter worth $2,803,000. 93.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on CORT shares. Weiss Ratings restated a “hold (c-)” rating on shares of Corcept Therapeutics in a report on Wednesday, June 24th. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Piper Sandler upped their price target on Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Finally, UBS Group set a $135.00 target price on Corcept Therapeutics in a research note on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.67.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.